<DOC>
	<DOCNO>NCT01857544</DOCNO>
	<brief_summary>The purpose study determine number patient complete resolution macular edema secondary central retinal vein occlusion follow 6 monthly injection Aflibercept .</brief_summary>
	<brief_title>Study Intravitreal Aflibercept Injection Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy</brief_title>
	<detailed_description>Twenty ( 20 ) consent participant meet inclusion criterion enrol follow 6 month . All subject receive monthly 2.0 mg intravitreal aflibercept injection .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>A patient must meet follow criterion eligible inclusion study : Age &gt; 18 year Documented macular edema follow central retinal vein occlusion Currently receive treatment intravitreal antiVEGF therapy initiate least 3 month month previously Documented intravitreal treatment ranibizumab 0.5 mg ( least 3 dos , one month apart ) bevacizumab 1.25 mg ( least 3 dos , one month apart ) Presence persistent macular edema ( define follow ) : central foveal thickness ( CFT ) &gt; 300 micron spectraldomain OCT presence intraretinal subretinal fluid Receipt intravitreal antiVEGF injection frequently per month Willingness ability comply clinic visit studyrelated procedure Ability provide sign informed consent Prior vitrectomy study eye Concurrent retinal vascular disease study eye could compromise visual acuity contribute macular edema ( e.g . diabetic retinopathy , agerelated macular degeneration ) Any concurrent intraocular condition study eye ( e.g . diabetic retinopathy , advanced glaucoma ) , opinion investigator , could either require medical surgical intervention 6month study period prevent treat visual loss ; , allow progress untreated , contribute loss least 2 Snellen equivalent line best correct visual acuity 6 month study period Active intraocular inflammation ( grade trace ) study eye , history idiopathic autoimmuneassociated uveitis either eye Current vitreous hemorrhage study eye Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye Intraocular surgery ( include cataract surgery ) study eye within 60 day precede baseline Systemic antiVEGF treatment within last 3 month prior screen Prior intravitreal aflibercept injection study eye Macular laser photocoagulation within 4 month screen Intravitreal periocular corticosteroid within 4 month screen Uncontrolled glaucoma study eye ( defined intraocular pressure â‰¥30 mmHg despite treatment ocular antihypertensive medication ) Allergy fluorescein , povidone iodine ( Betadine ) aflibercept Participation study investigational drug device within 30 day prior potential enrollment study Patients cognitive dysfunction dementia , Alzheimer 's disease neurodegenerative disorder . Pregnant breastfeed woman Sexually active men* woman childbearing potential** unwilling practice adequate contraception study ( adequate contraceptive measure include stable use oral contraceptive prescription pharmaceutical contraceptive 2 menstrual cycle prior screen ; intrauterine device ; bilateral tubal ligation ; vasectomy ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam , jelly ) Contraception require men document vasectomy . **Postmenopausal woman must amenorrheic least 12 month order consider child bear potential . Pregnancy test contraception require woman document hysterectomy tubal ligation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Retinal Vein Occlusion</keyword>
	<keyword>Central Retinal Vein Occlusion</keyword>
	<keyword>Macular Edema</keyword>
</DOC>